FIA
SGMT icon

FNY Investment Advisers’s Sagimet Biosciences SGMT Stock Holding History

FNY Investment Advisers’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-290
Closed -$1K – 1059
2025
Q4 		$1K Buy
290
+140
+93% +$1.01K ﹤0.01% 852
2025
Q3 		$1K Buy
+150
New +$1.22K ﹤0.01% 1180
2025
Q2 		– Sell
-470
Closed -$1K – 1166
2025
Q1 		$1K Buy
+470
New +$1.97K ﹤0.01% 689

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
FRM
Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

FNY Investment Advisers's SGMT Position: Q2 2026 in Review

FNY Investment Advisers reduced its Sagimet Biosciences (SGMT) stake by 27% in Q2 2026, selling an estimated $275K and leaving 109,250 shares worth $844K. The position accounts for 0.3% of the portfolio, ranked #100.

FNY Investment Advisers first reported a position in SGMT in Q1 2024 and has held it in 10 quarters since. The position peaked at $845K in Q4 2025. 31 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • FNY Investment Advisers held 109,250 shares of Sagimet Biosciences worth $844K as of Q2 2026.
  • FNY Investment Advisers sold 40,511 Sagimet Biosciences shares in Q2 2026, an estimated $275K.
  • Sagimet Biosciences made up 0.3% of FNY Investment Advisers's portfolio in Q2 2026, its #100 holding.
  • FNY Investment Advisers first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 10 quarters since.
  • FNY Investment Advisers's Sagimet Biosciences position peaked at $845K in Q4 2025.
  • 31 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.